# CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

> **NCT03511391** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 99 (actual)

## Conditions studied

- Urothelial Carcinoma
- Melanoma
- Renal Cell Carcinoma
- Non-small Cell Lung Cancer
- Head and Neck Cancer

## Interventions

- **DRUG:** Nivolumab or Pembrolizumab or Atezolizumab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT03511391
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-09
- **Primary completion:** 2022-02-01
- **Final completion:** 2024-01-23
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03511391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03511391, "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03511391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*